Sangiovanni A. et al. (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology, 126(4):1005-14.
Burroughs A. & McNamara D. (2003) Liver disease in Europe. Alimentary Pharmacology & Therapeutics, 18:54–59.
Smart R.G. Mann R.E. (1992) Alcohol and the epidemiology of liver cirrhosis. Alcohol Health Res World. 16:217-222.
Klatsky A.L. Armstrong M.A. Friedman G.D. (1993) Coffee, tea, and mortality. Ann Epidemiol. Jul;3(4):375-81.
Loomis D. et al. (2016) Carcinogenicity of drinking coffee, mate, and very hot beverages. The Lancet Oncology, 17(7):877-878.
Bravi F. et al. (2007) Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology, 46:430-435.
Larsson S.C. et al. (2007) Coffee consumption and liver cancer: a meta-analysis. Gastroenterology, 132:1740-1745.
Bravi F. et al. (2013) Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis. Clinical Gastroenterology and Hepatology, 11:1413-1421.
Leung W.W. et al. (2011) Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. Journal of Epidemiology & Community Health, 65:556-558.
Jang E.S. et al. (2013) The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver International, 33(7):1092-1099.
Lai G.Y. (2013) The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. British Journal of Cancer 109:1344–1351.
Setiawan V.W. et al. (2015) Association of Coffee Intake with Reduced Incidence of Liver Cancer and Death from Chronic Liver Disease in the US Multiethnic Cohort. Gastroenterol, 148(1):118-125.
Saab S. et al. (2014) Impact of coffee on liver disease a systematic review. Liver International 34(4):495-504.
Gressner O.A. (2009) About coffee, cappuccino and connective tissue growth factor – or how to protect your liver!? Environmental Toxicology and Pharmacology, 28(1):1-10.
Modi A.A. et al. (2010) Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology, 51:201-209.
Xiao Q. et al. (2014) Inverse association of total and decaffeinated coffee with liver enzymes in NHAMES 1999-2010. Hepatology, published online ahead of print. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25124935
Stroffolini T. et al. (2010) Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver International, 30(6):867-870.
Walton H.B. et al. (2013) An epidemiological study of the association of coffee with chronic liver disease. Scottish Medical Journal, 58(4):217-222.
Catalano D. et al. (2010) Protective role of coffee on non-alcoholic fatty liver disease (NAFLD). Digestive Disease and Sciences, 55(11):3200-3206.
Birerdinc A. et al. (2012) Caffeine is protective in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 35(1):76-82.
Molloy J.W. et al. (2012) Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology, 55(2):429-36.
Gutierrez-Grobe Y. et al. (2012) High coffee intake is associated with lower grade non-alcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals of Hepatology, 11(3):350-355.
Bambha K. et al. (2014) Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver International. 34(8):1250-8.
Freedman N.D. et al. (2009) Coffee intake is associated with lower rates of liver disease progression in chronic Hepatits-C. Hepatology, 50:1360–9.
Costentin C.E. et al. (2011) Association of caffeine intake and histological features of chronic hepatitis C. Journal of Hepatology, Volume 54; 1123-1129.
Sasaki Y. et al. (2014) Effect of caffeine containing beverage consumption on serum alanine aminotransferase levels in patients with chronic hepatitis C virus infection: a hospital based cohort study. PLoS One, 8(12):e83382.
Goh G.B. et al. (2014) Coffee, alcohol, and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatology, 60:661-9.
Gressner O.A. (2009) Less Smad2 is good for you? A scientific update on coffee’s liver benefits. Hepatology, 50, 970-978.
Gressner O.A. et al. (2009) Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in parenchymal cells. Liver International, 29(6):886-897.
Muriel P. et al. (2010) Coffee and liver disease. Fitoterapia, 81:297-305.
Wang G.W. et al. (2009) Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Research, 83(2):186-90.
EFSA (2015) Scientific Opinion on the Safety of Caffeine, EFSA Journal, 13(5):4102.
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2011) Scientific Opinion on the substantiation of health claims related to caffeine and increase in physical performance during short-term high-intensity exercise (ID 737, 1486, 1489), increase in endurance performance (ID 737, 1486), increase in endurance capacity (ID 1488) and reduction in the rated perceived exertion/effort during exercise (ID 1488, 1490) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal; 9(4): 2053 [24 pp.]. doi:10.2903/j.efsa.2011.2053
Neuhauser-Berthold M. et al (1997) Coffee consumption and total body water homeostasis as measured by fluid balance and bioelectrical impedance analysis. Ann Nutr Metab, 41(1):29-36.
Grandjean A.C. et al (2000) The effect of caffeinated, non caffeinated, caloric and non caloric beverages on hydration. J Am Coll Nutr, 19(5):591-600.
Maughan R.J. et al (2003) Caffeine ingestion and fluid balance: a review. J Hum Nutr Diet, 16(6):411-20.
Armstrong L.E. et al (2005) Fluid, electrolyte, renal indices of hydration during 11 days of controlled caffeine consumption. Int J Sport Nutr Exerc Metab, 15(3):252-65.
Silva A. M. et al (2013) Total body water and its compartments are not affected by ingesting a moderate dose of caffeine in healthy young adult males. Appl Physiol Nutr Metab, 38:626-632.
Tiedot on suunnattu terveydenhuollon ammattilaisille ja ravitsemusasiantuntijoille.